| Document |
Document Title |
|
WO/2002/079219 |
The present invention is based on the finding that 6-O-acyl-beta-D-glucosyl-beta-sitosterols extracted from fig latex were effective in inhibiting cell proliferation and thus may be used as anti-proliferative agents for the treatment of ...
|
|
WO/2002/072599 |
Efficacious intravenous preparations, skin preparations for external use, mucosal preparations for external use or cosmetics comprising novel ginsenoside derivatives (in particular, dihydroxyginsenoside Rb¿1? or epoxyginsenoside Rb¿1?)...
|
|
WO/2002/069977 |
The invention relates to the use of compounds to treat a number of conditions, such as thrombocytopenia, neutropenia or the delayed effects of radiation therapy. Compounds that can be used in the invention include methyl-2,3,4-trihydroxy...
|
|
WO/2002/055531 |
The present invention relates to novel compounds represented by the structure I and pharmaceutical preparations thereof for the treatment of inflammatory diseases in humans and animals.
|
|
WO/2002/055529 |
A method for recovering soy saponis which comprises extracting a soy isoflavone concentrate derived from soy molasses with a mixture of acetone and water, removing undissolved solids from the extract, cooling the extract such that soy sa...
|
|
WO/2002/038166 |
The present invention relates to methods and compositions for the use in treating type 2 diabetes and obesity. More specifically, the invention relates to the methods of screening for the active compound from berries from plants of the P...
|
|
WO/2002/019971 |
The invention relates to 17-Methylene steroids. Method for the production thereof and pharmaceutical compositions containing these compounds. The inventive compounds have an active profile with a hybrid character of such that they act as...
|
|
WO/2002/012266 |
There are provided according to the invention compounds of formula (I) wherein R¿1? represents C¿1-6? alkyl or C¿1-6? haloalkyl; R¿2? represents -C(=O)-aryl or -C(=O)-heteroaryl; R¿3? represents hydrogen, methyl (which may be in eit...
|
|
WO/2002/012265 |
According to one aspect of the invention, there is provided a compound of formula (I) and solvates thereof. There are also provided compositions containing the compound, processes for preparing it, and its use in therapy.
|
|
WO/2002/008243 |
The present invention relates inter alia to a novel oxidation process for the synthesis of a known intermediate, useful in the preparation of anti-inflammatory steroids, the known intermediate being of formula (I).
|
|
WO/2002/000679 |
Compounds of formula (I), where R is a monovalent cyclic organic group having from 3 to 15 atoms in the ring system, useful as pharmaceuticals.
|
|
WO/2001/098322 |
The present invention comprises the design, synthesis and development of a new class of chemotherapeutic agents for prophylactic and therapeutic treatments in a mammal, particularly a human, believed to be at risk of suffering from a hor...
|
|
WO/2001/092289 |
Efficacious intravenous preparations, skin preparations for external use, mucosal preparations for external use or cosmetics comprising ginsenosides, in particular, ginsenoside Rb or its derivative which are useful as skin tissue regener...
|
|
WO/2001/079256 |
A 19-norbufalin derivative compound of formula (I) and isomers pharmaceutically acceptable salts thereof. Compounds of formula (I) are Na?+¿,K?+¿-ATPase inhibitors and can be used in the treatment of cardiac and/or vascular malfunction...
|
|
WO/2001/049704 |
The present invention relates to the compounds of formula (I), a method for extracting it and a pharmaceutical composition containing it. The said extracting method includes: extracting the corpus radicis and/or radix fibrosa of a ginsen...
|
|
WO/2001/042273 |
This invention relates to methods for treating asthma or allergy in a mammal by administering a 3-aminosteroid compound to a mammal in need thereof. The 3-aminosteroid compound being capable of down regulating the IL-9 pathway and allevi...
|
|
WO/2001/032679 |
A novel glycoside compound for use in treating or preventing cardiovascular disease and it's underlying conditions such as atherosclersis and hypercholeterolemia comprises a carbohydrate moiety and a non-carbohydrate moiety wherein the c...
|
|
WO/2001/030802 |
The present invention provides methods and compositions to prevent or treat a hematopoietic disorder such as thrombocytopenia or neutropenia by administering to a subject an effective amount of a steroid such as 3,7,16,17-tetrahydroxy-an...
|
|
WO/2001/027132 |
A conjugated prodrug of an estradiol compound conjugated to a biological activity modifying agent.
|
|
WO/2001/015717 |
Medicinal compositions and preparations for administration comprising ginseng, which is useful as a cell protecting agent and a remedy for nerve trauma, its extract, ginseng components, metabolites thereof or salts thereof (for example, ...
|
|
WO/2001/002020 |
Novel pro-drugs and methods for their use to alter the growth and biological characteristics of living cells, tissues, or whole organisms are described. The methods allow for selective activation of the pro-drugs at or near transformant ...
|
|
WO/2001/000653 |
Novel phystosterol and/or phytostanol derivatives, including salts thereof, are represented by general formulae: (I), (II), (III), wherein R is a phytosterol or phytostanol moiety, R2 is derived from ascorbic acid and R3 is hydrogen or a...
|
|
WO/2000/066611 |
Steroid derivatives of this invention interact with nuclear liver X receptor (LXR) and ubiquitous receptor (UR) and can be used to treat a variety of LXR- or UR-mediated disorders.
|
|
WO/2000/066612 |
Androgen glycosides provide free, circulatory androgen on oral administration as they are subject to less, first pass breakdown by the liver.
|
|
WO/2000/056757 |
The invention provides compositions comprising formula 1 steroids, e.g., 16alpha-bromo-3beta-hydroxy-5alpha-androstan-17-one hemihydrate and one or more excipients, typically wherein the composition comprises less than about 3% water. Th...
|
|
WO/2000/048608 |
Efficacious preparations for intravenous administration containing ginsenoside Rb¿1? or its salt which are useful as vascular regeneration/reconstruction promoters and nerve tissue secondary degeneration inhibitors. These preparations a...
|
|
WO/2000/047215 |
The present invention provides novel methods, pharmaceutical compositions, and articles of manufacture for treating tumors that involve administering an effective amount of a cardiac glycoside, or a pharmaceutical salt thereof, wherein t...
|
|
WO/2000/039148 |
The invention relates to new 7$g(a), 17$g(a), 17$g(b)-substituted testosterone derivatives of general formula (I) and their use as pure antiandrogens for the long-term therapy of androgen-dependent diseases, notably for the long-term ant...
|
|
WO/2000/037481 |
Preparations for efficaciously administering ginsenoside Rb¿1? or its salt useful as cell-protective agents. More particularly, medicinal compositions for inhibiting apoptosis or apoptosis-like cell death or medicinal compositions for p...
|
|
WO/2000/034306 |
The invention is directed to a novel class of 17$g(b)-acyl-17$g(a)-propynyl steroids which exhibit potent antiprogestational activity.
|
|
WO/2000/032197 |
Compositions and methods for the treatment of retina and optic nerve head neuropathy are disclosed. The compositions and methods are particularly directed to the use of neurotrophic factor stimulators, such as AIT-082 (neotrofin), in the...
|
|
WO/2000/021977 |
This invention provides 5$g(a)-pregnane-3$g(b), (20S), 21-triol, 20-O-$g(b)-glucuronide and 5$g(a)-pregnane-3$g(b),20R-diol, 20-O-$g(b)-glucuronide and pharmaceutically acceptalbe salts thereof which are useful as progestational agents.
|
|
WO/2000/011018 |
The present invention relates to novel compounds comprising a steroid hormone linked to a DNA-interacting molecule that target nucleic acids to the cell nucleus. Further, the invention relates to a method for introducing nucleic acids in...
|
|
WO/2000/011019 |
The present invention relates to novel compounds comprising a steroid hormone linked to a DNA-interacting molecule that target nucleic acids to the cell nucleus. Further, the invention relates to a method for introducing nucleic acids in...
|
|
WO/1999/062928 |
The invention is directed to a novel class of steroids which exhibit potent antiprogestational activity.
|
|
WO/1999/052931 |
A medicine which contains a sialic acid derivative represented by formula (I) and is excellent in solubility and absorbability. It is a solid dispersion comprising a water-soluble polymer such as hydroxypropylmethylcellulose and disperse...
|
|
WO/1999/047542 |
Drugs containing as the active ingredient compounds having the following structure. These drugs are provided to develop compounds appropriate as anti-inflammatory agents suitable for topical administration (i.e., anti-inflammatory agents...
|
|
WO/1999/016786 |
The present invention relates to the use of steroid saponin compounds of formula (I) to prophylactic and therapeutic treatment of senility, for example Alzheimer's disease, and to novel steroid saponin compounds of formula (II), and the ...
|
|
WO/1999/016449 |
The present invention relates to Ca?2+¿ channel blockers and more particularly to the R-type Ca?2+¿ channel blockers. More specifically, the invention relates to Ca?2+¿ channel blockers activity of $i(Mandevilla velutina) and $i(Mande...
|
|
WO/1999/001467 |
There are described therapeutically active compounds or salts or solvates thereof, hydrolysable in human or animal blood to compounds with reduced therapeutic activity. There is also described a method of identifying a compound capable o...
|
|
WO/1998/051702 |
Compounds having an ansamycin antibiotic, or other moiety which binds to hsp90, coupled to a targeting moiety which binds specifically to a protein, receptor or marker can provide effective targeted delivery of the ansamycin antibiotic l...
|
|
WO/1998/050412 |
This invention provides 3$g(b)-hydroxy-5,7,9-estratriene-17-one and a pharmaceutically acceptable salt of its 3-sulfate ester, which is useful as an estrogen.
|
|
WO/1998/046243 |
A pharmaceutical composition contains an extract obtainable from a plant of the genus $i(Trichocaulon) or $i(Hoodia) containing an appetite suppressant agent having the formula (1). A process for obtaining the extract and a process for s...
|
|
WO/1998/045315 |
This invention provides estra-5(10),7-dien-3$g(b)-ol-17-one or a pharmaceutically acceptable salt of its 3-sulfate ester, estra-5(10),7-dien-3$g(b)-ol-17-one 3-glucuronide or a pharmaceutically acceptable salt thereof, estra-5(10),7-dien...
|
|
WO/1998/040399 |
Sterol compounds represented by general formula (I), wherein R represents nonyl or decyl. The sterol compounds can be synthesized by a technique or organic synthetic chemistry, and have improved antitumor activities.
|
|
WO/1998/009935 |
A process for preparing a compound having structure (I) wherein n is an integer from 1-5; each of R�1? and R�2? independently is optionally substituted C�1?-C�6? alkyl; each of W and X is independently hydrogen or C�1?-C�6? a...
|
|
WO/1998/002450 |
Steroid compounds having various oxygen substitution on the steroid nucleus are disclosed. A specific functionality present on many of the steroid compounds is oxygen substitution at both of positions 6 and 7. Thus, certain steroids have...
|
|
WO/1997/048401 |
A method of treating supraventricular arrhythmia and/or atrial fibrillation using a safe and effective amount of deoxy and oxygen-substituted sugar-containing 14-aminosteroid compounds and the pharmaceutically acceptable acid, salts or e...
|
|
WO/1997/045441 |
The present invention relates to the novel 7'alpha'-(5-methylaminopentyl)-estratrienes of the general formula (I), in which R2 is a hydrogen or fluorine atom, R17 is a hydrogen atom, a methyl or ethynyl group, n is 2, 3 or 4, and x is 0,...
|
|
WO/1997/038005 |
An antifungal and antilipemic agent comprising substance MK6059 of the following general formula (I) which is prepared by culturing a MK6059 strain belonging to the genus Ellisiodothis in a conventional nutrient medium for microbes, and ...
|
